Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 11 January 2026

Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

New York, January 11, 2026, 14:03 EST — Market closed. Merck & Co., Inc. shares closed down 0.4% on Friday at $110.53, and traders head into Monday with takeover chatter back in the tape. The Wall Street Journal reported Merck is in talks to buy Revolution Medicines in a deal valued around $28 billion to $32 billion. (The Wall Street Journal) Why it matters now: Merck is staring at a Keytruda patent cliff starting in 2028 — when exclusivity ends and cheaper rivals can start to bite into sales. The Financial Times said big drugmakers, including Merck and Bristol Myers
11 January 2026
······
AstraZeneca stock: Nasdaq-100 exit date nears as index flows and JPM conference loom

AstraZeneca stock: Nasdaq-100 exit date nears as index flows and JPM conference loom

London, Jan 11, 2026, 16:43 GMT — Market closed. AstraZeneca shares head into Monday’s session under pressure after Nasdaq announced Walmart will take the drugmaker’s spot in the Nasdaq-100 starting Jan. 20. (Reuters) This is significant today since index trackers often translate a calendar shift into actual trades. Funds following the Nasdaq-100 usually tweak their holdings near the effective date, causing spikes in volume and short-term price fluctuations. AstraZeneca’s shares in London finished Friday at 14,216 pence, gaining 0.28%. Over in the U.S., its ADRs closed at $94.65, up 0.68%, per Yahoo Finance. (Yahoo Finance) Nasdaq’s notice confirmed the change
11 January 2026
······
Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus

Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus

ZURICH, Jan 11, 2026, 17:40 CET — The market has closed. Roche Holding shares rose 0.4% on Friday following news that China’s MediLink Therapeutics inked a licensing deal with the Swiss pharma giant for an experimental cancer drug. The stock closed at 340.80 Swiss francs on the SIX Swiss Exchange. (MarketWatch) The deal underscores how big pharma continues to invest heavily in oncology pipelines, despite investor calls for more defined revenue prospects. Antibody-drug conjugates, or ADCs, remain a standout area in cancer R&D — leveraging antibodies to carry lethal agents directly to tumors. Timing is key for Roche. Shares are
11 January 2026
·····
Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

New York, Jan 11, 2026, 10:45 EST — Market closed. Shares of Johnson & Johnson (JNJ.N) dipped 0.7% on Friday to $204.39 following the company’s announcement of a deal with the Trump administration to lower U.S. drug prices. In return, J&J secured exemptions from certain U.S. tariffs. The company said it will offer medicines at discounted rates via TrumpRx.gov and match Medicaid pricing levels seen in other developed countries, though it did not specify which drugs would be involved or the exact discount sizes. The administration made similar deals with nine other pharmaceutical firms in December as part of its
11 January 2026
·····
Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

New York, Jan 11, 2026, 10:13 EST — Market closed Eli Lilly and Company shares dropped 1.99% on Friday, closing at $1,063.56. The stock heads into Monday’s session under pressure after a volatile week for major pharmaceutical firms. Investors are closely eyeing signs of a pricing battle in the obesity-drug sector after Amazon Pharmacy announced it now stocks Novo Nordisk’s Wegovy pill, available both through insurance and a cash-pay plan starting at $149 a month. Amazon added that eligible customers with commercial insurance might pay as little as $25 for a single month’s supply. The timing is key as the
11 January 2026
·········
OLMA stock jumps 10% into JPMorgan week — what to watch for Olema Pharmaceuticals

OLMA stock jumps 10% into JPMorgan week — what to watch for Olema Pharmaceuticals

New York, Jan 11, 2026, 08:51 (EST) — Market closed. Olema Pharmaceuticals Inc shares closed up 9.8% on Friday at $28.08, with about 2.5 million shares changing hands, as investors headed into a catalyst-heavy week for the cancer drug developer. (The Wall Street Journal) U.S. markets reopen on Monday, and Olema is the kind of stock that can gap on a single slide deck. Conference remarks and fresh sell-side research tend to matter more than broad market tape for early-stage biotechs, at least for a day or two. Olema said CEO Sean P. Bohen will present at the J.P. Morgan
11 January 2026
·····
NovaBay Pharmaceuticals stock jumps 102% — what to watch for NBY before Monday

NovaBay Pharmaceuticals stock jumps 102% — what to watch for NBY before Monday

New York, January 11, 2026, 07:38 EST — The market has closed. Shares of NovaBay Pharmaceuticals, Inc (NBY) soared Friday, closing up 102.5% at $19.16. The NYSE American stock will remain in focus when U.S. markets reopen Monday. (Daily Times Leader) Friday’s session ended a wild ride for the microcap, with shares bouncing between $9.69 and $19.95. Trading volume surged to roughly 10 million shares, a big jump from around 1.3 million the day before, according to stock data. (StockAnalysis) Why it matters now: investors are digging into older filings for signs of potential dilution — when new shares or
11 January 2026
·····
Haleon PLC stock: HLN slips on India leadership move as earnings loom

Haleon PLC stock: HLN slips on India leadership move as earnings loom

London, Jan 11, 2026, 09:53 GMT — Market closed Haleon PLC shares slipped 1.2% to 367.5 pence on Friday after the consumer health group named Kedar Lele to lead its India Subcontinent operations and join its senior leadership. (MarketScreener) The reason this matters now is straightforward. India’s market for everyday health brands moves quickly, shifting based on distribution, pricing discipline, and the intensity of new product launches. This lull in company news is typical. With earnings still weeks off, investors zero in on management changes, hunting for clues about future focus and spending. Haleon’s leadership team lists Lele as a
11 January 2026
·····
GSK stock in focus as Jemperli royalty fight escalates ahead of JPM conference

GSK stock in focus as Jemperli royalty fight escalates ahead of JPM conference

London, Jan 11, 2026, 08:35 GMT — The market has closed. Shares of GSK plc face fresh legal uncertainty on Monday after AnaptysBio moved to dismiss part of a contract claim related to royalties for the cancer drug Jemperli. On Friday, GSK slipped 0.26% to 1,886 pence, just shy of its 52-week peak at 1,909.5. Technical traders are eyeing the 1,830 pence level, close to the 200-day moving average, as a key support zone. Why it matters now: the royalty dispute comes at a critical moment, with healthcare investors bracing for a busy news week in San Francisco and GSK’s
11 January 2026
·····
TG Therapeutics stock slid nearly 7% Friday — what to watch next week for TGTX

TG Therapeutics stock slid nearly 7% Friday — what to watch next week for TGTX

New York, Jan 10, 2026, 21:40 (ET) — Market closed. TG Therapeutics shares fell 6.6% on Friday to close at $28.47, down $2.03, as the biotech stock swung between $28.21 and $30.83 on about 3.3 million shares. The drop leaves traders heading into a big week for healthcare stocks as the J.P. Morgan Healthcare Conference opens Monday in San Francisco. “We have seen deals get approved that could have had more regulatory risk in the past,” JPMorgan banker Jeremy Meilman said in a Reuters report on the gathering. (Reuters) TG Therapeutics sells Briumvi, an anti-CD20 antibody approved in the United
11 January 2026
····
Liquidia stock jumps after $148 mln Yutrepia sales update — what to watch next week

Liquidia stock jumps after $148 mln Yutrepia sales update — what to watch next week

New York, Jan 10, 2026, 19:48 EST — Market closed Shares of Liquidia Corp surged 12.9% on Friday, closing at $35.86 following a preliminary sales update on its pulmonary hypertension drug YUTREPIA. The company also reported positive cash flow in Q4. During the session, the stock hit a high of $38.07 and was trading about 1.5% higher in after-hours, per Yahoo Finance data. (Yahoo Finance) For Liquidia, the question remains: can YUTREPIA sustain its early momentum, or will script rates flatten as the launch matures? This week, that question gains weight as the company’s update arrives just before the J.P.
11 January 2026
·····
Olema Pharmaceuticals stock jumps 10% into JPM conference week: what OLMA traders are watching next

Olema Pharmaceuticals stock jumps 10% into JPM conference week: what OLMA traders are watching next

New York, Jan 10, 2026, 20:48 ET — Market closed Shares of Olema Pharmaceuticals Inc (OLMA.O) jumped nearly 10% on Friday, closing at $28.08 and extending the biotech’s strong rally. The clinical-stage breast cancer drugmaker has been on a notable upswing recently. This move is crucial as next week marks a pivotal period for small and mid-cap biotech firms. Executives will scatter around San Francisco for the annual J.P. Morgan Healthcare Conference, while investors demand solid timelines instead of lofty promises. Olema’s CEO Sean P. Bohen will speak on Jan. 13 at 11:15 a.m. PT (2:15 p.m. ET). The company
11 January 2026
····
1 … 17 18 19 20 21 … 56

Stock Market Today

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 07.02.2026

7 February 2026
LIVEMarkets rolling coverageStarted: February 7, 2026, 12:00 AM ESTUpdated: February 7, 2026, 12:27 AM EST Dollar Dips as Stocks Rally and US Data Influences Fed Rate Expectations February 7, 2026, 12:18 AM EST. The **dollar index** fell 0.17%, pressured by a rebound in equity markets reducing demand for the safe-haven currency. Weaker-than-expected U.S. labor market data raised the odds of a Fed rate cut to 18% for March, though consumer sentiment improved to a six-month high, limiting losses. Hawkish comments from Atlanta Fed's Raphael Bostic emphasized maintaining restrictive monetary policy. The dollar faces medium-term weakness amid expectations for rate cuts
Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop